TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34143971
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus IBI305 (200 mg every 3 weeks and 15 mg/kg every 3 weeks respectively)
Study: 34170062
Drug: Individualized medical
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized medical therapy
Study: 32196506
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of praziquantel (40 mg/kg)
Study: 32196506
Drug: Four repeated
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four repeated doses of praziquantel (40 mg/kg) administered at two-week intervals
Study: 35209934
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) capsules taken orally on day 1, day 7, and day 14
Study: 35209934
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken orally on day 1, day 7, and day 14
Study: 32917259
Drug: Flow-controlled ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow-controlled ventilation for 48 hours with settings starting at pre-existing PEEP, tidal volume of 6 ml/kg lean body mass, and respiratory rate to maintain arterial pH above 7.2.
Study: 35032379
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% and Bupivacaine 0.25% with 25 μg of Epinephrine
Study: 34787868
Drug: Logotherapy (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logotherapy (10 sessions, 90 min each, twice a week)
Study: 35366664
Drug: Alternating doses
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating doses of pentazocine and acetaminophen
Study: 33525480
Drug: Multicolored leaves
Normalized name: digitalis leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicolored leaves (ML)
Study: 33902293
Drug: Bach flower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bach flower remedies (BFR) - 30% hydro-brandy solution with two drops each of Impatiens, White Chestnut, Cherry Plum, Chicory, Crab Apple, and Pine, orally ingested (4 drops, 4 times a day for 4 weeks)
Study: 33595680
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (specific treatment not detailed)
Study: 33595680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specific treatment not detailed)
Study: 35820629
Drug: KL130008 (1–20
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL130008 (1–20 mg single doses or 2–6 mg multiple doses once daily for seven days)
Study: 34548526
Drug: Individually calculated
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually calculated loading regimen (weekly capsules)
Study: 34548526
Drug: Monthly drinking
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly drinking solution (24,000 IU vitamin D)
Study: 34548526
Drug: Monthly capsules
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly capsules (24,000 IU vitamin D)
Study: 38115002
Drug: RTS,S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S vaccine
Study: 32389453
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration 1 ng/mL
Study: 32389453
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration 2 ng/mL
Study: 32389453
Drug: Remifentanil effect-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil effect-site concentration 3 ng/mL
Study: 38184008
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily for 7 days
Study: 34331551
Drug: Indobufen 100
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 100 mg twice daily for 1 month
Study: 34331551
Drug: Aspirin 50
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 50 mg twice daily, 75 mg once daily, 50 mg once daily
Study: 34331551
Drug: Aspirin given
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin given every second or third day
Study: 39110846
Drug: Vortioxetine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5-20 mg/day)
Study: 34488408
Drug: Six-month anti-TB
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month anti-TB therapy
Study: 34488408
Drug: Nine-month anti-TB
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-month anti-TB therapy
Study: 35892319
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper extremity therapy
Study: 33360679
Drug: ASK120067 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASK120067 (oral irreversible tyrosine kinase inhibitor)
Study: 33360679
Drug: ASK120067 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASK120067 (oral administration)
Study: 33788609
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies (acetaminophen, NSAIDs, opioids, benzodiazepines, Gabapentin, Neurontin, cortisone injections)
Study: 33788609
Drug: Nondrug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrug therapies (self-care treatments, massage, acupuncture, spinal manipulation, physical therapy)
Study: 33788609
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment recommendations
Study: 33788609
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to treatment recommendations
Study: 35160276
Drug: Carbohydrate-enriched drink
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-enriched drink (NutriciaTM Pre-op®) 400 mL
Study: 32842315
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg of CpG ODN recombinant (Hansenula polymorpha) Hepatitis B vaccine
Study: 32842315
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg of commercial Hepatitis B vaccine
Study: 33806310
Drug: Daratumumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab alone or as part of combination regimens
Study: 34418903
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg orally for 2 weeks, taken half an hour before bedtime in low light conditions)
Study: 34418903
Drug: Control (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (regular medications)
Study: 34705072
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PRP (n: 62)
Study: 34705072
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of PRP (n: 63)
Study: 34705072
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of sodium saline (NS) (n: 59)
Study: 34705072
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of sodium saline (NS) (n: 53)
Study: 33579594
Drug: Dosage
Normalized name: Note Dosage Strength Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage
Study: 36210434
Drug: Differentiated digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated digital intervention (ART medication messages, medication reminders, peer education, online discussion)
Study: 34134469
Drug: Extended maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended maintenance with subcutaneous rituximab, n=138
Study: 33782116
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (left-leaning and right-leaning media)
Study: 32641226
Drug: Sacubitril/Valsartan (S/V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (S/V) titrated to 97 mg/103 mg twice daily
Study: 34496085
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (2g amoxicillin preoperatively and 500mg tid for 7 days postoperatively)
Study: 34496085
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same preoperative dose of amoxicillin and placebo postoperatively)
Study: 34496085
Drug: Implant survival
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant survival rate
Study: 32224896
Drug: Paclitaxel-Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-Cisplatin (80 mg/m2 weekly + 20 mg/m2 triweekly cisplatin)
Study: 32224896
Drug: Paclitaxel-Carboplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-Carboplatin (80 mg/m2 weekly + AUC 5 triweekly carboplatin)
Study: 32224896
Drug: Chemotherapy duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy duration >21 weeks
Study: 32100494
Drug: Electronic moxibustion
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic moxibustion at Lianquan (CV 23), Tiantu (CV 22), Tianding (LI 17), and Futu (LI 18), 30 min each treatment, 5 times a week for 4 weeks.
Study: 32100494
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment, acupuncture treatment, and swallowing rehabilitation training.
Study: 35261120
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 mcg every 6 h up to 48 h)
Study: 35261120
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (starting with 50 units up to a maximum of 300 units)
Study: 35261120
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (second-line treatment)
Study: 35261120
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (second-line treatment)
Study: 32098758
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg sprifermin every 6 months (q6mo)
Study: 32098758
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg sprifermin every 6 months (q6mo)
Study: 32098758
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg sprifermin every 12 months (q12mo)
Study: 34481898
Drug: Best endovascular
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best endovascular treatment (BET)
Study: 33055007
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in NLR early during chemotherapy
Study: 33847362
Drug: Cytisinicline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline 1.5 mg
Study: 33847362
Drug: Cytisinicline 3
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline 3 mg
Study: 33847362
Drug: Cytisinicline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline 1.5 mg TID
Study: 33847362
Drug: Cytisinicline 3
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisinicline 3 mg TID
Study: 35057084
Drug: Placebo—oral (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo—oral (Group A)
Study: 35057084
Drug: Placebo—sublingual (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo—sublingual (Group B)
Study: 35057084
Drug: Oral standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard aspirin—100 mg daily (Group C)
Study: 35057084
Drug: Oral standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral standard aspirin—50 mg daily (Group D)
Study: 35057084
Drug: Standard sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sublingual aspirin—100 mg (Group E)
Study: 35057084
Drug: Standard sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sublingual aspirin—50 mg (Group F)
Study: 35057084
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of micronized collagen-cogrinded aspirin (Groups G and H)
Study: 35057084
Drug: Sublingual collagen-cogrinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual collagen-cogrinded aspirin—100 mg (Group I)
Study: 35057084
Drug: Sublingual collagen-cogrinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual collagen-cogrinded aspirin—50 mg (Group L)
Study: 33225464
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Oral-B Kids)
Study: 35938597
Drug: Boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
Study: 35732751
Drug: ZoneX #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZoneX #2 (5.8 mg nicotine/pouch)
Study: 35732751
Drug: ZoneX #3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZoneX #3 (10.1 mg nicotine/pouch)
Study: 33771837
Drug: Inebilizumab 300
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inebilizumab 300 mg
Study: 35460388
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron therapy (2*80 mg iron sulfate)
Study: 35460388
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day oral iron therapy (2*80 mg iron sulfate)
Study: 35156503
Drug: Recreational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational music therapy (RMT)
Study: 32301116
Drug: Identifying treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identifying treatment effect modifiers
Study: 33917201
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) treatment
Study: 34661821
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus NSAIs (150 mg)
Study: 34661821
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus NSAIs (150 mg)
Study: 32092505
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin (dual pathway inhibition regimen)
Study: 34844156
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.3 g/kg body weight/day for 14 days)
Study: 34844156
Drug: Control (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (25 g of sugar in 250 mL of water)
Study: 33092558
Drug: Conditional cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional cash incentive for education (education treatment arm)
Study: 33092558
Drug: Conditional raffle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional raffle for testing negative for curable STIs (in both education treatment and control arms)
Study: 35305955
Drug: LABR‐312 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABR‐312 infusion (0.01 mg, 0.03 mg, and 0.08 mg)
Study: 35700588
Drug: Immunomodulating (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating (IM) supplements
Study: 35700588
Drug: High-protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (HP) supplements
Study: 34554208
Drug: Ivosidenib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (500 mg, once daily)
Study: 32350174
Drug: CHO gel
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO gel (commercially available jelly drink)
Study: 33030273
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (350 mg/day)
Study: 32396017
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant (NZBC) extract (two capsules of 300 mg each, 7-day intake)
Study: 36149885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.5 mg letrozole and 50 mg clomiphene (CC)
Study: 36075200
Drug: Hemadsorption therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemadsorption therapy (HT) using a CytoSorb® adsorber for up to 5 days, replaced every 18-24 hours.
Study: 36075200
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT).
Study: 36075200
Drug: Hemadsorption therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemadsorption therapy (HT)
Study: 32147046
Drug: Mulberry leaves
Normalized name: digitalis leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry leaves (12 mg of mulberry DNJ three times daily)
Study: 32147046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg of DNJ)
Study: 35797235
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) AZD7442, 600 mg
Study: 35797235
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) AZD7442, 300 mg
Study: 34984028
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D 5000 IU once daily plus standard treatment (pregabalin, gabapentin, or amitriptyline) for 8 weeks
Study: 33289129
Drug: C‐dots at
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐dots at a concentration of 530 g L‐1
Study: 35126684
Drug: SHR4640 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 10 mg plus febuxostat 80 mg
Study: 35126684
Drug: SHR4640 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 10 mg plus febuxostat 40 mg
Study: 35126684
Drug: SHR4640 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 5 mg plus febuxostat 20 mg
Study: 34554694
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) treatment of the saphenous nerve
Study: 34554694
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham procedure with motor stimulation)
Study: 32121066
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Undaria pinnatifida fucoidan (UPF)
Study: 35720066
Drug: Safinamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide (50 mg/day for 2 weeks and 100 mg/day for 22 weeks)
Study: 36367004
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg and sufentanil (NS1)
Study: 36367004
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg and sufentanil 20 mg (NS2)
Study: 36367004
Drug: Nalbuphine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 30 mg and sufentanil 20 mg (NS3)
Study: 33471169
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium citrate
Study: 32694705
Drug: Non-pharmaceutical dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmaceutical dry eye therapy
Study: 32694705
Drug: Daily saline
Normalized name: SODIUM CHLORIDE 0.9 g in 100 mL NASAL AEROSOL, SPRAY [EQUATE DAILY SALINE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily saline eye wash
Study: 33930408
Drug: Teprotumumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (8 infusions every 3 weeks)
Study: 32002650
Drug: 4-aminopyridine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine for the symptomatic treatment of episodic ataxia type 2 and downbeat nystagmus
Study: 615413969
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus thrice-weekly progressive aerobic exercise (S+PAE)
Study: 615413969
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus thrice-weekly non-progressive exercise (S+NPE)
Study: 34941317
Drug: Shared decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision-making (SDM) for treatment planning (n = 20)
Study: 34941317
Drug: Clinician-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided treatment planning (n = 20)
Study: 33484027
Drug: Ivabradine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine plus conventional treatment (IG)
Study: 33484027
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (CG)
Study: 33385766
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 100 mg/day
Study: 33238677
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (0.6 ml/kg)
Study: 32017660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment program consisting of only modalities, range of motion [ROM], and strength training but no PSSEs)
Study: 33068819
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control with no treatment
Study: 33469832
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg extended release